



TuBerculosis Vaccine Initiative

Draft Programme

Annual TBVI Meeting

Innovating and Delivering TB Vaccines and Biomarkers

6 – 7 April 2022

Hotel Eurotel Victoria
Les Diablerets
Switzerland



TuBerculosis Vaccine Initiative

Wednesday 6 April

Maison des Congres

08.30 – 08.40 Welcome and Introduction – Nick Drager, TBVI Netherlands

08.40 – 09.00 TB vaccine R&D Portfolio - towards next generation vaccines – *speaker tbc*

09.00 – 09.20 Title (tbc) - Michael Kazatchkine, Switzerland (tbc)

09.20 – 12.00 **Session 1. Mechanisms of immune protection: vaccination strategies to accelerate and maintain local immune protection. (Chairs Andrea Cooper / Rasmus Mortensen)**

09.30 – 09.30 Introduction/overview

- Andrea Cooper, United Kingdom

09.30 – 10.00 Local immune responses in the lung

- Daniel Barber, United States

10.00 – 10.30 *Coffee/Tea – Maison des Congres*

10.30 – 10.45 Maturation of iBALT can be mediated by vaccination and serve as backdoor for T cells to the Mycobacterium tuberculosis (Mtb) infected lung

- Thomas Lindenstrom, Denmark

10.45 – 11.00 Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis.

- Elena Mata, Spain

11.00 – 11.30 Division of labor in the lung during pulmonary infection

- *speaker tbc*

11.30 – 11.45 Intravital imaging

- Emma Lefrancais, France

11.45 – 12.00 A protective role for lung Interstitial CD4+ T cells
Lessons from HIV/Mtb co-infection

- Bjorn Corleis, Germany

12.00 – 13.10 *Lunch - Restaurant Eurotel*



TuBerculosis Vaccine Initiative

Wednesday 6 April (afternoon)

Maison des Congres

- 13.30 – 16.00 **Session 2. Towards next generation TB vaccines: innovation of the pipeline through new delivery platforms and novel vaccination routes (Chairs: Mei Mei Ho/Camille Locht).**
- 13.30 – 13.40 Update since the end of TBVAC2020 –
Mei Mei Ho, United Kingdom
Camille Locht, France.
- 13.40 – 14.05 Alternative delivery routes for (re)vaccination using live TB vaccines towards enhanced efficacy
Frank Verreck, Netherlands
- 14.05 – 14.25 New platform / delivery routes
speaker tbc
- 14.25 – 14.45 Nanoparticle-fusion proteins and mucosal vaccination
Rajko Reljic, United Kindom.
- 14.45 – 15.05 Lentiviral vectors expressing Mtb antigens
Laleh Majlessi, France.
- 15.05 – 15.25 A new Mtb specific protein-adjuvant vaccine that bypass T-cell-imprint from BCG and improve protection
Rasmus Mortensen, Denmark
- 15.25 – 15.40 CysVAC TB vaccines
Warwick Britton, Australia.
- 15.40 – 16.00 *Coffee/Tea – Maison des Congres*
- 16.00 – 17.25 **Session 3. Correlates of protection: innovating and validating the pipeline (Chairs: Hazel Dockrell/Tom Ottenhoff)**
- 16.00 – 16.25 Major achievements TBVAC2020 WP5
Simone Joosten, Netherlands.
- 16.25 – 17.00 Correlates of protection and clinical TB vaccine development
Tom Scriba, South Africa.
- 17.00 – 17.25 What can we learn from TB BM in NHP?
Sally Sharpe, United Kingdom
- 17.25 – 17.35 *Photo whole group outside in front of the Maison des Congres*
- 18.30 - 19.15 *Reception – Bar/Entrance Hall Eurotel*
- 19.15 *Dinner - Restaurant Eurotel*



TuBerculosis Vaccine Initiative

Thursday 7 April 2022

Maison des Congres

08.30 – 09.40 **Session 3. Correlates of protection: innovating and validating the pipeline** (Chairs: Hazel Dockrell/Tom Ottenhoff)

- | | | |
|---------------|--|-------------------------------|
| 08.30 – 08.55 | High dimensional analysis of pulmonary responses in TB | Erin McCaffrey, USA. |
| 08.55 – 09.20 | The macrophage problem: What is it and how can we resolve it. | David Russell, USA. |
| 09.20 – 09.40 | Host transcriptomic biomarkers through TB treatment with Diabetes comorbidity. | Jackie Cliff, United Kingdom. |

09.40 – 10.10 *Coffee/Tea – Maison des Congres*

10.10 – 12.00 **Session 4. - Experimental Medicine and Clinical Trials** (Chairs: ~~Helen McShane~~, Bernard Fritzell)

- | | | |
|---------------|---|-----------------------------------|
| 10.10 – 10.30 | Introduction/overview | - <i>tbc.</i> , United Kingdom. |
| 10.30 – 10.50 | Adaptive clinical trials | - Mark Hatherill, South Africa. |
| 10.50 – 11.10 | BCG as a vaccine for COVID-19 | - Nigel Curtis, Australia. |
| 11.10 – 11.30 | Lessons from COVID-19 | - Frank Cobelens, Netherlands |
| 11.30 – 11.40 | Therapeutic vaccination in tuberculosis: phase I/II randomized clinical trial of H56:IC31 and adjunctive Cyclooxygenase-2-inhibitor treatment | - Anne-Ma Riise, Norway |
| 11.40 – 12.00 | Controlled human challenge studies for TB vaccines | - Brian Robertson, United Kingdom |

12.00 – 12.30 Break



TuBerculosis Vaccine Initiative

Thursday 7 April 2022 (afternoon)

12.30 – 13.20 Short talks ongoing trials in TBVAC2020/EDCTP Projects

12.30 – 12.40	ChAdOx1 85A Aerosol/MVA 85A IM	- Francois Spertini, Switzerland (<i>tbc</i>)
12.40 – 12.50	MTBVAC coming to Phase 3 Trial	- Ingrid Murillo, Spain.
12.50 – 13.00	VPM1002	- Leander Grode, Germany.
13.00 – 13.10	H56/IC31	- Alvaro Borges, Denmark.
13.10 – 13.20	RUTI	- Pere Joan Cardona, Spain.

13.20 – 13.30 Closure meeting – (*speaker tbc*)

Side meetings

14.45 – 16.15 TBVI Steering Committee Meeting (for SC members only) (*room Diablerets, Eurotel*)

14.45 – 16.45 EDCTP meeting (for EDCTP members only) (*room ?? – Eurotel*)

17.00 – 18.00 P&CDT meeting (for P&CDT members only)

19.00 *Dinner - Restaurant Eurotel*